menu ☰
menu ˟

Biologics application submitted for osteoporosis drug

23 Jul 2016
A Biologics License Application for romosozumab, an investigational monoclonal antibody much anticipated as a therapy for the treatment of osteoporosis in postmenopausal women at high risk for fracture, has been submitted to the FDA by co-developers ...

Click here to view the full article which appeared in Endocrinology

Please note

The news articles accessible on the Health Well website have been compiled from various sources that are not controlled by the Institute of Public Health in Ireland (IPH). IPH is therefore not responsible for the content of external websites and the inclusion of a link to an external website from the Health Well should not be understood to be an endorsement of that website.